Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
ILLUMINA, INC. director Daniel Skovronsky reported an acquisition of 1,674 shares of common stock through a grant of restricted stock units. These RSUs were valued at $164.28 per share for reporting purposes and represent his entire reported direct holding after the transaction.
According to the grant terms, 100% of the shares subject to this restricted stock unit award will vest on the earlier of the one-year anniversary of the grant date or the date immediately preceding the company’s next annual stockholder meeting for the following year, as long as he continues to serve as a director through that date.
ILLUMINA, INC. director Daniel Skovronsky filed an initial Form 3, which is a statement of beneficial ownership required when someone becomes an insider. The filing does not report any buy or sell transactions and serves mainly to put his insider status on record with regulators.
Illumina, Inc. increased its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D. as a director, effective June 16, 2026. He will stand for election at the company’s 2027 annual meeting of stockholders for a one-year term.
Dr. Skovronsky is deemed an independent director under applicable Nasdaq and SEC rules and will participate in Illumina’s non-employee director compensation programs. He currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing deep experience in drug discovery, clinical development, and translational medicine relevant to Illumina’s genomics and multiomics platforms.
Illumina, Inc. senior vice president and Chief People Officer Patricia Leckman reported open-market sales of a total of 783 shares of common stock. The sales on June 5 occurred at prices ranging from $161.79 to $167.88 per share. After these transactions, she holds 21,259 shares directly.
Illumina filing a Form 144 notice for proposed resale of common shares. The excerpt lists broker/dealer UBS Financial Services, Nasdaq listing, and several security line items including PSU entries dated 02/21/2023 and 02/22/2022. The excerpt also shows a 06/05/2026 filing date and a selling holder identified as The Patricia L Leckman Trust dtd 5/21/2014.
ILLUMINA, INC. senior vice president and chief people officer Patricia Leckman reported open-market sales of a total of 784 shares of common stock on June 2, 2026. The shares were sold in multiple trades at weighted average prices around $160.66, $162.00, and $163.02 per share, within disclosed price ranges between $160.30 and $163.33. Following one of these transactions, she held 22,042 common shares directly.
Frances Arnold reported proposed insider sales of Common Stock under a Form 144 notice. The filing lists prior dispositions and restricted shares vesting under registered plans.
The filing shows recent dispositions of 5,000 shares on 05/28/2026 for $780,650, 3,000 shares on 05/22/2026 for $435,076.08, and 1,000 shares on 05/22/2026 for $145,072.06. It also lists restricted stock vesting entries of 1,175, 322, and 1,503 shares on their respective vesting dates.
ILLUMINA, INC. reported that private investment funds advised by Corvex Management LP, entities associated with director Keith A. Meister, executed a series of indirect open-market sales of common stock. Across May 28–29 and June 1, the Corvex Funds sold an aggregate 669,596 shares at weighted-average prices generally between about $147.50 and $165.50 per share, as detailed in multiple price ranges.
The filing states that both Corvex and Mr. Meister disclaim beneficial ownership of these securities except to the extent of their pecuniary interest. The Corvex Funds also terminated equity swaps that had provided economic exposure comparable to 368,744 shares. On termination of 24,562 notional shares, the swaps counterparty paid the Corvex Funds $3,841,496.80 based on $156.40 per share, offset by $2,525,464.84 reflecting a $102.82 per-share cost, with the swap exercise and related stock purchases deemed exempt under Rule 16b-6(b).
ILLUMINA, INC. Chief Legal Officer Scott M. Davies reported an open-market sale of company stock. On May 29, 2026, he sold 615 shares of common stock at $160.00 per share. After this transaction, he directly holds 21,568 shares of Illumina common stock.